This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagle, R. B. Articles by Celniker, A. Search for Related Content PubMed PubMed Citation Articles by Nagle, R. B. Articles by Celniker, A.

Cytokeratin Characterization of Human Prostatic Carcinoma and Its Derived Cell Lines¹

Department of Pathology [R. B. N., K. M. M., V. A. C.], University of Arizona School of Medicine, and Section of Hematology and Oncology [F. R. A., A. C.] and Department of Pathology [M. L. P.], Tucson Veterans Administration Medical Center, Tucson, Arizona 85724

Two murine monoclonal anti-cytokeratin antibodies with defined specificity were shown to distinguish between basal cells and luminal cells in human prostate tissue. Forty-one biopsies or transurethral resection specimens were characterized using these two antibodies. In cases of benign prostatic hyperplasia, focal loss of the basal cell layer was noted in areas of glandular proliferation. Ten cases of adenocarcinoma of the prostate, varying in Gleason's histological grade from 2 to 4, were also studied. In each case the carcinoma was shown to represent the luminal cell phenotype with no evidence of involvement of the basal cell phenotype. An analysis of three established metastatic prostatic carcinoma cell lines (DU-145, PC-3, and LNCaP) using two-dimensional electrophoresis showed that the cytokeratin complement of each cell line was slightly different but retained the phenotype of the luminal cell. It was concluded that during both hyperplasia and neoplastic transformation of the prostate, the luminal cell phenotype is primarily involved and that the basal cell phenotype does not appear to contribute to either intraluminal proliferation or invasive cell populations.

¹ Supported in part by a V.A. Merit Review Grant and a University of Arizona Cancer Center Institutional Grant.

² To whom requests for reprints should be addressed, at Department of Pathology, College of Medicine, Arizona Health Sciences Center, 1501 North Campbell Avenue, Tucson, AZ 85724.

Received 6/ 4/86. Revised 9/ 8/86. Accepted 9/11/86.

This article has been cited by other articles:

				R.U. Lukacs, D.A. Lawson, L. Xin, Y. Zong, I. Garraway, A.S. Goldstein, S. Memarzadeh, and O.N. Witte Epithelial Stem Cells of the Prostate and Their Role in Cancer Progression Cold Spring Harb Symp Quant Biol, November 6, 2008; (2008) sqb.2008.73.012v1. [Abstract] [PDF]

				T. Reiner, A. de las Pozas, R. Parrondo, and C. Perez-Stable Progression of Prostate Cancer from a Subset of p63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice Mol. Cancer Res., November 1, 2007; 5(11): 1171 - 1179. [Abstract] [Full Text] [PDF]

				D. Floryk, S. L. Tollaksen, C. S. Giometti, and E. Huberman Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5'-Monophosphate Dehydrogenase Cancer Res., December 15, 2004; 64(24): 9049 - 9056. [Abstract] [Full Text] [PDF]

				S. Singh, S. Sadacharan, S. Su, A. Belldegrun, S. Persad, and G. Singh Overexpression of Vimentin: Role in the Invasive Phenotype in an Androgen-independent Model of Prostate Cancer Cancer Res., May 1, 2003; 63(9): 2306 - 2311. [Abstract] [Full Text] [PDF]

				C. P. Tran, C. Lin, J. Yamashiro, and R. E. Reiter Prostate Stem Cell Antigen Is a Marker of Late Intermediate Prostate Epithelial Cells Mol. Cancer Res., December 1, 2002; 1(2): 113 - 121. [Abstract] [Full Text] [PDF]

				S. Signoretti, D. Waltregny, J. Dilks, B. Isaac, D. Lin, L. Garraway, A. Yang, R. Montironi, F. McKeon, and M. Loda p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development Am. J. Pathol., December 1, 2000; 157(6): 1769 - 1775. [Abstract] [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				R Pankov, I Simcha, M Zoller, R. Oshima, and A Ben-Ze'ev Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma J. Cell Sci., January 4, 1997; 110(8): 965 - 974. [Abstract] [PDF]